$56 Million

PhaseBio Pharmaceuticals, Inc.

Follow-on Offering

Lead Left Bookrunner, March 2021

PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc. (the “Company” or “PhaseBio”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases. The Company’s lead product candidate, bentracimab (also known as PB2452), is a novel reversal agent for the antiplatelet drug ticagrelor, which the Company is developing for the reversal of the antiplatelet effects of ticagrelor in patients with uncontrolled major or life-threatening bleeding or requiring urgent surgery or an invasive procedure. PhaseBio’s second product candidate, pemziviptadil (also known as PB1046), is a once-weekly fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension, or PAH. The Company is also developing their preclinical product candidate, PB6440, for treatment-resistant hypertension.